Ebola Outbreak Escalates, Spotlighting Demand for TOMI’s Disinfection Tech
Event summary
- WHO declares Ebola outbreak a Public Health Emergency of International Concern with over 500 suspected cases and 130 fatalities.
- Bundibugyo strain of Ebola, with no broadly available vaccine, raises urgency for containment efforts.
- TOMI’s SteraMist technology previously deployed in West Africa to contain Ebola, now positioned for potential global demand.
- TOMI supports healthcare, life sciences, hospitality, and defense sectors with disinfection solutions.
The big picture
The escalating Ebola outbreak underscores the critical need for advanced disinfection technologies in global health security. TOMI’s SteraMist, proven in previous outbreaks, is well-positioned to capitalize on heightened demand for infection control solutions. The lack of a vaccine for the Bundibugyo strain amplifies the strategic importance of TOMI’s offerings in both public health and private sector applications.
What we're watching
- Outbreak Severity
- Whether the Bundibugyo strain’s rapid spread and lack of vaccine will drive sustained demand for TOMI’s solutions.
- Government Contracts
- How TOMI’s prior success with WHO and USAID positions it for new public-sector deals.
- Market Expansion
- The pace at which TOMI can scale production and deployment of SteraMist to meet global health emergencies.
Related topics